This Fund Bought $63 Million of Chemours Stock Even as Shares Sit 80% Below 2017 Highs

Cooper Creek Partners initiated a new position in The Chemours Company during Q3, acquiring nearly 4 million shares valued at $63.1 million as of September 30, representing 1.9% of the fund’s 13F-reportable AUM (the fund reported $3.3 billion in U.S. equity holdings across 88 positions). Chemours shares closed at $12.79 (down ~41% Y/Y); company TTM revenue is $5.8 billion with TTM net income of -$320 million, but Q3 results showed stabilization with $1.5 billion revenue and $60 million net income (vs. a prior-year loss), and a 2.7% dividend yield. The purchase signals institutional interest in a depressed chemical name amid operational improvement, though leverage and end-market cyclicality remain key risks for investors.

Analysis

Market structure: Cooper Creek’s new $63M stake signals an institutional re-appraisal of Chemours (CC) as a specialty-chemical + refrigerant play rather than a pure TiO2 cyclic. Winners: Chemours’ Opteon refrigerant franchise, suppliers of fluorochemicals, and service providers to HVAC/R; losers: low-cost TiO2 competitors if demand softens further. The buy suggests market participants are pricing cyclically-driven revenue weakness rather than a permanent franchise impairment — if Opteon growth continues, Chemours can recapture margin and share versus peers over 6–24 months.

Risk assessment: Key tail risks are legacy environmental liabilities (PFAS litigation/regulatory action), a sharper-than-expected TiO2 end-market downturn, and credit-market stress that lifts Chemours’ borrowing costs; any of these could compress equity to single digits quickly. Immediate (days) volatility will track news flow and 13F visibility; medium-term (3–12 months) outcomes hinge on Q4 results and guidance; long-term (>12 months) depends on deleveraging and successful margin mix shift. Hidden dependency: Opteon pricing is sensitive to refrigerant regulation (EPA/EU) and feedstock fluorochemical supply disruptions.

Trade implications: Direct long exposure should be staged and size-capped given leverage: starter position 2–3% portfolio at <$13, add to 4–6% if < $10; trim to take profits if > $20 within 12–24 months. Pair trade: long CC vs short TROX (Tronox) 1:1 notional for 6–12 months to isolate TiO2 cyclicality while benefiting from Chemours’ refrigerant upside. Options: use an 18-month call spread (e.g., Jan 2027 15C/25C) to express upside with defined cost, and buy 6–9 month 10P puts as downside protection.

Contrarian angles: Consensus treats CC as a broken cyclic; that may underweight recurring Opteon cash flow and simplifying balance-sheet optionality (asset sales, targeted divestitures). Reaction may be overdone if management executes deleveraging — similar to past chemical turnarounds where public equity recovered 2x–3x after 12–36 months of stabilization. Unintended consequence: a rally could attract short-covering and squeeze if credit spreads don’t retrace, producing asymmetric near-term upside.

Key Decisions for Investors

• Establish a phased long equity position in CC totaling 2–3% of portfolio at current price (~$12.79); add incrementally to reach 4–6% only if CC falls below $10 within next 6 months. Target hold 12–24 months, trim half if share price reaches $20.
• Implement a relative-value pair: go long CC and short TROX (Tronox) equal notional size for 6–12 months to isolate Opteon-specific upside; close if spread narrows <5% or if both names report synchronized margin deterioration.
• Buy an 18-month call spread on CC (example: Jan 2027 15C / 25C) sized to ~1% portfolio risk to capture asymmetric upside while capping cost; concurrently purchase a 6–9 month 10P protective put to limit downside to ~$10 on stock moves triggered by PFAS or credit shocks.
• Avoid buying Chemours’ corporate bonds or increasing credit exposure until reported net leverage falls below ~3.0x adjusted EBITDA on consecutive quarter filings; monitor credit spreads — consider long CDS protection if 5Y spreads widen >200bp from current levels within 90 days.
• Monitor three near-term catalysts before scaling: Q4 earnings (next 45–90 days) for Opteon revenue/margin trends, any PFAS/regulatory filings or settlements, and quarterly net leverage. If management provides clear deleveraging plan and guidance confirms Opteon growth, increase position; if litigation or leverage deteriorates, exit to protective puts.